VVOS · XBRL financial data
Vivos Therapeutics financial statements, every fiscal year
The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (VVOS's year ends in late December)
| In millions of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue from contracts with customers | 13 | 17 | 16 | 14 | 15 | 17 |
| Cost of revenue | — | — | — | 6 | 6 | 7 |
| Cost of goods and services sold | 0 | 0 | 0 | 0 | — | — |
| Gross profit | 10 | 13 | 10 | 8 | 9 | 11 |
| Research and development | — | 0 | 0 | 0 | 0 | 0 |
| General and administrative | 16 | 26 | 29 | 22 | 18 | 28 |
| Total operating expenses | 22 | 33 | 35 | 26 | 20 | 30 |
| Operating income (loss) | (12) | (20) | (25) | (17) | (11) | (20) |
| Interest expense | 0 | 0 | — | — | — | 1 |
| Other income (expense) | — | (0) | (0) | (0) | (0) | (1) |
| Net income (loss) | (12) | (20) | (24) | (14) | (11) | (21) |
| Earnings per share, basic USD per share | — | (0.96) | (1.04) | (11.14) | (2.22) | (2.07) |
| Earnings per share, diluted USD per share | — | — | (25.90) | (11.14) | (2.22) | (2.07) |
| Weighted average shares, basic millions of shares | — | 21,233 | 23,012 | 1 | 5 | 10 |
| Weighted average shares, diluted millions of shares | — | — | 1 | 1 | 5 | 10 |
- † Share count changed about 1/11 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (VVOS's year ends in late December)
| In millions of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 18 | 24 | 4 | 2 | 6 | 2 |
| Accounts receivable | 1 | 1 | 0 | 0 | 0 | 2 |
| Prepaid and other current assets | 1 | 2 | 1 | 1 | 1 | 1 |
| Total current assets | 20 | 27 | 5 | 2 | 7 | 4 |
| Property and equipment, net | 1 | 3 | 3 | 3 | 3 | 4 |
| Right-of-use asset | — | — | 2 | 1 | 1 | 4 |
| Goodwill | 3 | 3 | 3 | 3 | 3 | 9 |
| Total assets | 25 | 34 | 14 | 11 | 15 | 25 |
| Accounts payable | 1 | 1 | 1 | 2 | 1 | 2 |
| Accrued liabilities | 2 | 3 | 2 | 2 | 2 | 6 |
| Current portion of long-term debt | 1 | 1 | — | — | — | 8 |
| Total current liabilities | 8 | 8 | 7 | 7 | 5 | 18 |
| Long-term debt | 0 | — | — | — | — | 0 |
| Lease liability, non-current | — | 0 | 2 | 2 | 1 | 4 |
| Total liabilities | 8 | 8 | 9 | 10 | 7 | 27 |
| Accumulated deficit | (35) | (56) | (79) | (93) | (104) | (125) |
| Total stockholders' equity | 17 | 26 | 5 | 0 | 8 | (1) |
| Total liabilities and equity | 25 | 34 | 14 | 11 | 15 | 25 |
| Common shares outstanding (cover page) millions of shares | 18 | 23 | 30 | 3 | 6 | 13 |
- † Share count changed about 1/11 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (VVOS's year ends in late December)
| In millions of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (12) | (20) | (24) | (14) | (11) | (21) |
| Stock-based compensation | 2 | 3 | 2 | 1 | 1 | 1 |
| Depreciation and amortization | — | 1 | 1 | 1 | 1 | 1 |
| Net cash from operating activities | (6) | (16) | (20) | (12) | (13) | (15) |
| Purchases of property and equipment | 0 | 2 | 1 | 1 | 1 | 2 |
| Net cash from investing activities | (0) | (3) | (1) | (1) | (1) | (8) |
| Proceeds from issuing common stock | 22 | 28 | — | 4 | 8 | 6 |
| Proceeds from long-term debt | — | — | — | — | — | 11 |
| Repayments of long-term debt | 0 | 0 | — | — | — | — |
| Net cash from financing activities | 24 | 24 | — | 11 | 18 | 19 |
| Net change in cash | 18 | 6 | (21) | (2) | 5 | (4) |
- † Share count changed about 1/11 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Vivos Therapeutics | 1.8 | 5.2 | (3.1)* | 20.1M | 0.6 quarters | 10-QJun 30, 2026 |
| Positron | 0.4 | 0.1 | (1)* | 32.8M | 0.3 quarters | 10-QJun 30, 2026 |
| United Health Products | 0 | 0 | (0.1)* | 262.7M | 0.2 quarters | 10-QJun 30, 2026 |
| Allurion Technologies | 5.1 | 2.9 | (3.2) | 15.0M | 1.6 quarters | 10-QMar 31, 2026 |
| Neuroone Medical Technologies | 2 | 2 | (1.1)* | 9.1M | 1.9 quarters | 10-QJun 30, 2026 |
| Precision Optics | 9.8 | 8.8* | (0.6)* | 11.0M | 15.2 quarters | 10-KJun 30, 2026 |
| Neuraxis | 8.3 | 1.9 | (1)* | 12.6M | — | 10-QJun 30, 2026 |
| RenovoRx | 9.5 | 0.9 | (2.9)* | 45.1M | 3.3 quarters | 10-QJun 30, 2026 |
| Dror Ortho-Design | 0.1 | not reported | (0.3)* | 977.0M | 0.3 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.